Abstract
We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50% lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50%, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.
| Original language | English |
|---|---|
| Pages (from-to) | 92-97 |
| Number of pages | 6 |
| Journal | Modern Rheumatology |
| Volume | 17 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2007 Apr |
| Externally published | Yes |
Fingerprint
Keywords
- Cyclosporine A
- Immunosuppressivedrugs
- Lupusnephritis
- Systemiclupus erythematosus
ASJC Scopus subject areas
- Rheumatology
- Immunology
Cite this
Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. / Ogawa, Hiroe; Kameda, Hideto; Nagasawa, Hayato; Sekiguchi, Naoya; Takei, Hirofumi; Tsuzaka, Kensei; Amano, Koichi; Takeuchi, Tsutomu.
In: Modern Rheumatology, Vol. 17, No. 2, 04.2007, p. 92-97.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis
AU - Ogawa, Hiroe
AU - Kameda, Hideto
AU - Nagasawa, Hayato
AU - Sekiguchi, Naoya
AU - Takei, Hirofumi
AU - Tsuzaka, Kensei
AU - Amano, Koichi
AU - Takeuchi, Tsutomu
PY - 2007/4
Y1 - 2007/4
N2 - We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50% lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50%, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.
AB - We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50% lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50%, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.
KW - Cyclosporine A
KW - Immunosuppressivedrugs
KW - Lupusnephritis
KW - Systemiclupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=34247247141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247247141&partnerID=8YFLogxK
U2 - 10.1007/s10165-006-0545-8
DO - 10.1007/s10165-006-0545-8
M3 - Article
C2 - 17437162
AN - SCOPUS:34247247141
VL - 17
SP - 92
EP - 97
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 2
ER -